Selective IL-2 deprivation in Tregs using anti-IL-2Rα (CD25) monoclonal antibodies combined with CD40 receptor activation has demonstrated synergistic effects, maintaining durable immune responses in lymphoma models and highlighting the potential of these therapies in tumor microenvironment modulation (111). Here, IL2 is linked to neoplasm.